FRα Antibody-Drug Conjugates for Targeted Camptothecin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates targeting folate receptor alpha (FRα) for cancer treatment have limitations in efficacy and specificity, particularly in overexpressing cancer cells, and there is a need for improved ADCs with enhanced therapeutic effects.
Innovation Solution
Development of antibody-drug conjugates (ADCs) comprising an anti-FRα antibody construct linked to a camptothecin analogue via a specific linker, with defined antigen-binding domains and linker structures, targeting human folate receptor alpha (hFRα) to enhance cancer cell inhibition and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current ADCs targeting FRα are used for cancer treatment, then some anti-tumor activity is achieved, but efficacy and specificity are limited particularly in overexpressing cancer cells
Solution Approach 1:
The patent applies local quality by designing ADCs with site-specific conjugation at defined positions on the antibody molecule (e.g., at the N-terminus of the light chain or at specific cysteine residues). This ensures that the cytotoxic payload is delivered precisely to cells that overexpress FRα, enhancing both efficacy and specificity while minimizing off-target effects.
Solution Approach 2:
The patent utilizes parameter changes by optimizing the drug-to-antibody ratio (DAR), linker structure, and payload type to enhance therapeutic efficacy. By adjusting these parameters, the ADCs achieve improved stability, enhanced cellular internalization, and increased cytotoxicity specifically in FRα-overexpressing cancer cells.
2Productivity
If ADCs with higher payload delivery are designed, then cancer cell killing capability improves, but receptor-mediated internalization efficiency may be compromised
Solution Approach 1:
The patent employs a specially designed linker as an intermediary between the antibody and the cytotoxic payload. This linker (e.g., peptide-based linkers like GGGGCV or VC-PABC) facilitates efficient receptor-mediated internalization while maintaining payload stability, thereby balancing internalization efficiency with cancer cell killing capability.
Solution Approach 2:
The patent applies preliminary action by pre-optimizing the linker-payload conjugation structure before administration. The linkers are designed to remain stable during circulation but undergo specific cleavage (e.g., by cathepsin B or pH-dependent hydrolysis) within the target cell, ensuring that high payload delivery occurs only after successful internalization, thus maintaining both internalization efficiency and killing capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADCs demonstrate improved receptor-mediated internalization, payload delivery, and cancer cell killing capabilities, showing significant anti-tumor activity in various cancer models, including ovarian and lung cancer xenografts and PDX models.
Implementation Method 1
an anti-FRα antibody construct comprising an antigen-binding domain that specifically binds to an epitope within human folate receptor alpha (hFRα)
Implementation Method 2
The ADCs demonstrate improved receptor-mediated internalization, payload delivery, and cancer cell killing capabilities
Implementation Method 3
D is a compound of Formula I... showing significant anti-tumor activity in various cancer models
Data Source
AI summary
Antibody-drug conjugates (ADCs) comprising an antibody construct that binds specifically binds human folate receptor alpha (FRα) (an anti-FRα antibody construct) conjugated to a camptothecin analogue of Formula (I). The ADCs are useful as therapeutics, in particular in the treatment of cancer.